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Abstract
Background Hereditary nonpolyposis colorectal cancer
(HNPCC) is the most common cause of early onset
hereditary colorectal cancer. In the majority of HNPCC
families, microsatellite instability (MSI) and germline
mutation in one of the DNA mismatch repair (MMR)
genes are found.
Materials and methods The entire coding sequence of
MMR genes (MLH1, MLH2, MLH6, and PMS2) was
analyzed using direct sequencing. Also, tumor tests were
done as MSI and immunohistochemistry testing.
Results We were able to find three novel MLH1 and one
novel PMS2 germline mutations in three Iranian HNPCC
patients. The first was a transversion mutation c.346A>C
(T116P) and happened in the highly conserved HATPase-c
region of MLH1 protein. The second was a transversion
mutation c.736A>T (I246L), which caused an amino acid
change of isoleucine to leucine. The third mutation (c.2145,6
delTG) was frameshift and resulted in an immature stop
codon in five codons downstream. All of these three
mutations were detected in the MLH1 gene. The other
mutation was a transition mutation, c.676G>A (G207E),
which has been found in exon six of the PMS2 gene and
caused an amino acid change of glycine to glutamic acid.
MSI assay revealed high instability in microsatellite for two
patients and microsatellite stable for one patient.
Conclusion In all patients, an abnormal expression of the
MMR proteins in HNPCC was related to the above novel
mutations.
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Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC or
Lynch syndrome) is an autosomal dominantly inherited
cancer-susceptibility syndrome and is the most common
cause of hereditary colorectal cancer with an early age of
onset. It is estimated that HNPCC may account for 5–10%
of the total colorectal cancers worldwide [1–3]. In Western
countries, patients inheriting this predisposition are at a
particularly high risk of developing colorectal cancer [2, 4].
HNPCC is associated with germline mutations in the
mismatch repair (MMR) genes, which include MLH1
(MIM#120436), MSH2 (MIM#120435), PMS2 (MIM
#600259), and MSH6 (MIM #600678) [5, 6]. About 90%
of the identified germline mutations in the MMR genes are
found in two genes, MLH1 and MSH2 [7]. Currently, more
than 300 different mutations have been described in these
genes, which account for approximately 500 HNPCC
kindred in the world [8].
Also, microsatellite instability (MSI) is found in some of
the HNPCC families and provides an opportunity for
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genetic diagnosis. The MMR gene mutations spectrum and
MSI variations vary across different populations [9, 10].
Identification of the mutational incidence and spectrum
of MMR genes and MSI variations is important to
developing successful diagnostics and therapeutic strategies
in different populations [10, 11]. Our objective was to
detect and study MSI and the MMR gene germline
mutation carriers among the Iranian population with
colorectal cancer.
Materials and methods
Patients and controls
The study was approved by the local institutional review
board. Blood samples (for germline mutation analysis) and
paired paraffin-embedded blocks of cancerous tissue (for
the MSI analysis) were collected from 592 unrelated
patients with HNPCC, and 248 healthy individuals from
the Iranian normal population as controls. Cases and
controls were recruited through a large multiclinic gastro-
enterology practice. Paraffin-embedded sections were ex-
amined by two experienced pathologists.
Diagnosis of HNPCC was done in a three-stage process
including review of family cancer history, tumor testing,
and genetic testing.
Review of family cancer history A complete medical
history and a physical examination were performed. All
patients had a complete physical examination by the same
physician. To determine if a patient is at risk for HNPCC,
the following criteria are used: (1) At least two relatives
with an HNPCC-associated cancer, including colon, rectal,
endometrial, small bowel, ureter, or renal pelvis cancer. (2)
One of the two relatives is a first-degree relative of the
other two, such as a parent, child, or sibling. (3) At least
two generations of relatives are affected. (4) At least one
relative is diagnosed with cancer before the age of 50. (5)
No family history of familial adenomatous polyposis (an
inherited disorder unrelated to HNPCC). Individuals who
meet the above criteria were considered to have HNPCC in
their family.
Tumor testing Tests were done on removed tumors (even
those removed years before). Tests included: (1) MSI
testing—looks for the presence of genetic instability
associated with HNPCC. (2) Immunohistochemistry test-
ing—samples of tumor tissue were stained to look for the
presence of proteins associated with this disease.
Genetic testing If the review of family cancer history and
tumor testing suggested the likelihood of an HNPCC
genetic mutation, the next step was to consider having the
blood test for the presence or absence of an HNPCC genetic
mutation.
DNAwas extracted from 10 mL blood and from three to
five sections of each 10-µm-thick paraffin-embedded
sample (around 0.01–0.02 g of tissue) using a High Pure
PCR Template Preparation Kit (Roche Diagnostics, Ger-
many) and eluted into 150 µL of elution buffer. The eluted
DNA was stored at −20°C until further use.
Pathological analysis
The size of each tumor was evaluated by measuring its
two greatest axes in order to calculate the surface area in
square centimeters. Tumors located from the cecum up to
and including the splenic flexure were considered
proximal, and those from the descending colon to the
rectum distal [12].
The pathological type, grading, and staging were
confirmed from the original microscopy slides which were
Table 1 Primer sequences for MSI assay
Name Gene GenBank number Repeat Primer sequences Amplicon size (bp)
NR-27 Inhibitor of apoptosis
protein-1
AF070674 27 A 5′UTR F: AACCATGCTTGCAAACCACT 87
R:CGATAATACTAGCAATGACC
NR-21 SLC7A8 XM 033393 21 T 5′UTR F: GAGTCGCTGGCACAGTTCTA 109
R: CTGGTCACTCGCGTTTACAA
NR-24 Zinc finger 2 X60152 24 T 3′UTR F: GCTGAATTTTACCTCCTGAC 131
R: ATTGTGCCATTGCATTCCAA
BAT-25 c-kit X06182 25 T intron 16 F: TACCAGGTGGCAAAGGGCA 153
R: TCTGCATTTTAACTATGGCTC
BAT-26 hMSH2 U04045 26 A intron 5 F: CTGCGGTAATCAAGTTTTTAG 183
R: AACCATTCAACATTTTTAACCC
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reviewed separately by two pathologists. Grading was
evaluated according to the World Health Organization
histological classification. Tumors with a regular glandular
structure were considered to be “well”-differentiated; those
with a structure between well-differentiated and poorly
differentiated were defined as “moderately” differentiated.
Those with a solid/trabecular architectural structure or
mucus-secreting cells which were difficult to recognize
were termed as “poorly” differentiated [13].
Immunohistochemical staining
A variety of antigen retrieval methods were evaluated in
a pilot study and checker-board titrations were performed
to determine the most favorable method of staining.
Optimum results were obtained using heat-mediated
antigen retrieval and following the Envision method.
Immunohistochemical (IHC) analysis for the expression
of MLH1, MSH2, MSH6, and PMS2 proteins was
performed on 5-µm-thick sections of paraffin-embedded
cancerous tissue blocks. The tissue sections were
deparaffinized in xylene and rehydrated in graded
concentrations of alcohol. Endogenous peroxidase activ-
ity was blocked by treating the sections with blocking
solution. For antigen retrieval, the sections were treated
while boiling in citrate buffer [pH 9.0] in a microwave.
Sections were incubated with primary antibodies hMLH1
(BD Biosciences Pharmingen; clone G168-15, 1:100
dilution), hMSH2 (Calbiochem, Oncogene Sciences;
clone FE11, 1:100 dilution), hMSH6 (BD Transduction
Laboratory; clone 44,1:1,000 dilution), and PMS2 (BD
Pharmingen; clone A16-4, 1:500 dilution). After each
step, slides were washed with TBS buffer for 3 min.
Then, slides were treated with Envision (Dako, REAL
Envision) for 20 min. To visualize immunoreaction, 3,2′-
diaminobenzidine was used, and samples were counter-
stained with hematoxylin. Intramucosal lymphocytes
were used as positive controls [14].
Microsatellite instability assay
The MSI analysis was performed on paired tumoral DNA
from cancerous tissues and genomic DNA from whole
blood, using five loci in the USA National Cancer
Institute (NCI) panel (NR-27, NR-21, NR-24, BAT-25,
and BAT-26; Table 1). MSI carriers were identified by
analysis of tumor tissue using polymerase chain reaction
(PCR) according to the NCI recommended panel and
classified into microsatellite instability-low (MSI-L),
microsatellite instability-high (MSI-H), and microsatellite
stable (MSS) [15–17].
Germline mutation analysis
The entire MLH1, MSH2, MSH6, and PMS2 coding
regions and the splice junctions were amplified by PCR,
according to previously published methods [18]. The
primers which were used for amplification of exons 4, 9,
and 19 of the MLH1 gene and exon 6 of the PMS2 gene,
which included new mutations, are summarized in Table 2.
PCR amplicons for each exon were sequenced bidirec-
tionally. Sequencing was performed using the Big Dye
Table 2 Primer sequences for germline mutation analysis
Exon and gene Exon length (bp) Primer length (mer) Ta (°C) Amplicon size (bp) Primers sequence
Exon4-MLH1 70 22 61.8 479 F: TTCAGATAACCTTTCCCTTTGG
R: AGCAATACCCCAACTGAAGG
Exon9-MLH1 110 22 65.6 335 F: AATGGATGGATGAATGGACAGG
R: GTGGGTGTTTCCTGTGAGTGG
Exon19-MLH1 168 21 56.3 397 F: AAAAAATCCTCTTGTGTTCAG
R: GGAATACAGAGAAAGAAGAACAC
Exon6-PMS2 165 20 62.1 443 F: GCGATGATGTGAGAACCTTG
R: GAGCCAAGACAACACCACTG
Patient's ID Site of cancer Age at diagnosis Stage Grade Criteria
832037F Splenic flexure 52 IIA Well.diff B&A
831847A Ascending colon 52 pT3, pN0, M0 Mod.diff B&A
882230H Hepatic flexure 77 IIA Mod.diff None
Table 3 Characteristics of the
patients with novel MMR gene
mutations
B Bethesda criteria, A Amster-
dam criteria II
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terminator cycle sequencing kit v.3.1 (Applied Biosys-
tems, Foster City, CA, USA), and the products were
analyzed on the ABI 3130XL genetic analyzer (Applied
Biosystems). Any variation in DNA sequence was
confirmed by repeating the bidirectional sequencing on
an independent PCR product.
Bioinformatics analysis of frameshift mutation in MLH1
protein
To better understand the pathogenicity of frameshift
mutation in exon 19 of the MLH1 gene which causes the
replacement of five amino acids, immature stop codon, and
Fig. 1 IHC staining. a Patient with two missense mutations in exons
four and nine of the MLH1 gene had abnormal expression of the
MLH1 protein (loss of nuclear staining) and normal IHC for the other
MMR proteins. b Patient with frameshift mutation in exons 19 of the
MLH1 gene had abnormal expression of the MLH1 protein (loss of
nuclear staining) and normal IHC for the other MMR proteins. c
Patient with missense mutations in exon 6 of the PMS2 gene had
abnormal expression of the PMS2 protein (loss of nuclear staining)
and normal IHC for the other MMR proteins
Table 4 MLH1 and PMS2 germline mutations in patients with HNPCC
Patient's ID Gene Exon Codon Nucleotide changea Consequence HIC result MSI status GenBank accession no.
832037F MLH1 4 116 c.346A>C p.Thr116Pro Neg.MLH1 MSI-H EF570786
832037F MLH1 9 246 c.736A>T p.Ile246Leu Neg.MLH1 MSI-H EF570787
831847A MLH1 19 715, 716 c.2145,6 delTG p.Thr715ThrfsX5 Neg.MLH1 MSS EF125076
882230H PMS2 6 207 c.676G>A p.Gly207Glu Neg.PMS2 MSI-H EF583852
a Numbering based on cDNA sequence, position +1 corresponds to the A of the ATG translation initiation codon in reference sequence; MLH1
[GenBank NM_000249], PMS2 [GenBank: NM_ 000535]
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Fig. 2 MSI assay. For each
patient, there are two panels,
cancerous tissue (upper) to
check the rate of MSI and paired
normal sample (lower) as
control. a Patient with two
missense mutations in exons
four and nine of the MLH1 gene
had high instability in micro-
satellite analysis (five out of five
instable markers). b Patient with
frameshift mutation in exon 19
of the MLH1 gene had com-
pletely normal panel (MSS). c
Patient with missense mutations
in exon 6 of the PMS2 gene had
high instability in microsatellite
analysis (four out of five
instable markers)
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loss of 41 amino acids in the C-terminal of the protein, we
performed the complete bioinformatics analysis of the
MLH1 protein including normal sequence and protein
sequence after frameshift mutation using CLC Protein
Workbench software (CLC bio USA).
Results
After all exons of MLH1, MSH2, MSH6, and PMS2 were
amplified and sequenced in HNPCC patients, we found
four novel germline mutations: three missense mutations in
exon 4, exon 9, and exon 19 of the MLH1 gene and one
missense mutation in exon 6 of the PMS2 gene (Table 4).
Case report
Patient 1 A 52-year-old woman, 832037F, was diagnosed
during a routine colonoscopy with a well-differentiated
adenocarcinoma in the splenic flexure of the colon,
measuring 5.5 cm2 in diameter. Lymph node metastases
were not present (pt1 (sm1) pN0, M0). The TNM
classification of the adenocarcinoma was determined as
IIA. The patient fulfilled the Bethesda and the Amsterdam
(II) criteria.
Patient 2 Samples were obtained from a 52-year-old man,
831847A, fulfilling the Bethesda and the Amsterdam (II)
criteria, with a carcinoma of the ascending colon, measur-
ing 9.9 cm2 in diameter. The TNM classification was
documented as pT3, pN0, M0. The patient was treated by
right hemicolectomy. HNPCC screening was initiated,
promoted by the findings of colonic cancers with histolog-
ical features suspicious of HNPCC.
Patient 3 A 77-year-old man, 832230H, who met neither the
Bethesda nor the Amsterdam criteria (II), was diagnosed with
colorectal carcinoma. Histopathological analysis revealed a
Fig. 3 Sequencing result for
novel mutations. a c.346A>C
(T116P) transversion mutation
in exon 4 of the MLH1 gene. b
c.736A>T (I246L) transversion
mutation in exon 9 of the MLH1
gene. c c.2145,6delTG frame-
shift mutation in exon 19 of the
MLH1 gene. d c.676G>A
(G207E) transition mutation in
exon 6 of the PMS2 gene
Fig. 4 Bioinformatics analysis of the MLH1protein before and after
frameshift mutation. a Partial sequence of the MLH1protein contains
exon 19 and α-helix domains. b–d Compared antigenicity, hydropho-
bicity, and protein charge analysis of normal and mutant MLH1
protein after frameshift mutation in exon 19. Black arrows indicate
important differences between normal and mutant proteins
b
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6.8-cm2 polypoid carcinoma in the hepatic flexure of the
colon. TNM classification was documented as IIA. Screen-
ing for HNPCC was initiated because of the conspicuous
histological findings, although the patient did not fulfill both
criteria. Medical histories of the patients carrying these novel
mutations are summarized in Table 3.
IHC staining
IHC analysis of MMR protein expression (MLH1, MSH2,
MSH6, and PMS2) was performed for all patients. All cases
with defects in the expression of one of theMMRproteinswere
referred for MSI analysis and genotyping. Figure 1 shows the
defects of MLH1 protein expression in two patients and
PMS2 protein expression in one patient with HNPCC.
MSI assay
After checking the MSI panel for patients with novel
mutation, one patient with two missense mutations in the
MLH1 gene (832037F) and the patient with missense
mutations in the PMS2 gene (832230H) had MSI-H. One
patient with frameshift mutation in the MLH1 gene
(832047F) had MSS panel (Table 4 and Fig. 2).
Mutation screening
In the MLH1 gene, the first mutation was a transversion
mutation of 346A→C (numbering of nucleotide position
followed the GenBank accession number NM_000249),
which causes amino acid change of threonine to proline at
position 116 of the MLH1 polypeptide chain in exon 4. The
second mutation was a transversion mutation of 736A→T in
exon 9, which causes amino acid change of isoleucine to
leucine at position 736 of the MLH1 polypeptide. The third
mutation was a frameshift mutation of 2145, 6, with deletion
of two nucleotides (TG) in exon 19, which causes frameshift
amino acid change of exon 19 in the MLH1 polypeptide
(Fig. 3).
In the PMS2 gene, the mutation was a transition mutation
of 676G→A (numbering of nucleotide position followed the
GenBank accession number NM_000535), which causes
amino acid change of glycine to glutamic acid at position
207 of the PMS2 polypeptide chain in exon 6 (Fig. 3).
In all mutations, the sequencing from the opposite
direction of the product from another PCR was done to
confirm these mutations (data not shown).
Mutation nomenclature
Nucleotide numbering was based on the MLH1 cDNA
sequence (GenBank NM_000249; [gi:28559089]), with the
A of the ATG translation initiation codon at position 61.
Current mutation nomenclature recommendations (http://
www.hgvs.org/mutnomen) suggest numbering the A of the
ATG translation initiation codon as +1. The numbering of
the reported mutations is as follows: c.346A>C or p.
Thr116Pro (T116P), c.736A>T or p.Ile246Leu (I246L), and
c.2145, 6delTG or p.Thr715ThrfsX5.
Nucleotide numbering for the PMS2 gene was performed
according to the cDNA sequence (GenBank NM_000535;
[gi:102470225]), with the A of the ATG translation
initiation codon at position 87. The numbering of the
reported mutation is as follows: c.676G>A or p.Gly207Glu
(G207E). All of these four novel mutations were submitted
to the GenBank (GenBank accession numbers are summa-
rized in Table 4).
Bioinformatics analysis of frameshift mutation in MLH1
protein
Bioinformatics analysis showed that, after frameshift muta-
tion in exon 19 of the MLH1 protein, antigenicity and
hydrophobicity of MLH1 decreased, but the protein charge
did not change. Also, as a result of this mutation, mutant
protein lost three important α-helix domains in the C-
terminal of the protein. This means that the deleted sequence
due to the immature stop codon might have a critical role in
protein folding and conformation, and the pathogenicity of
mutation is related to these changes (Fig. 4).
Discussion
We report four novel germline mutations (three inMLH1 and
one in PMS2 MMR genes) in HNPCC patients, which have
not been found in the normal Iranian population nor reported
by any other member of the research groups. Under these
circumstances, polymorphisms could be ruled out.
Patient 832037F showed two missense mutations in
exons four and nine of the MLH1 gene (c.346A>C and
c.736A>T, respectively). The c.346A>C mutation was in
the highly conserved HATPase-c region of the MLH1
protein and created an amino acid change of threonine with
the hydroxyl group to proline with the amide group.
Threonine is a completely neutral amino acid, but despite
its nonionic nature, the amide groups of praline are
markedly polar. As a result of the second mutation (c.
736A>T), the amino acid isoleucine was changed to
leucine. Both are aliphatic amino acids and do not contain
heteroatoms (N, O, or S) in their side chains or a ring
system. Their side chains are markedly apolar. This change
is considered a tolerated change, and the pathogenicity of
HNPCC in this patient mostly related to the first mutation.
In this patient, the tumor was immunohistochemically
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negative regarding the expression of the MLH1 protein and
normal expression of MSH2, MSH6, and PMS2 proteins.
This patient had high instability in microsatellite analysis
(five out of five instable markers).
Patient 831847A carried pathogenically two nucleotide
germline deletions in exon 19 of the MLH1 gene (c.2145,6
delTG), causing a frameshift and resulting in an immature
stop codon in five codons downstream. As a result of this
frameshift mutation, five amino acids downstream from the
mutation changed (GTHCL vs. VEHIV), and due to the
immature stop codon, 41 amino acids in the C-terminal of
the MLH1 protein were deleted (VEHIVYKALR-
SHILPPKHFTEDGNILQLANLPDLYKVFERC). The tu-
mor was highly microsatellite unstable (five out of five
instable markers), and IHC showed no expression of the
MLH1 protein, but normal expression of other MMR
proteins. Genetic testing in one of his sons was positive
for the same mutation.
Patient 882230H demonstrated a missense mutation in
exon six of the PMS2 gene (c.676G>A), causing replace-
ment of glycine with glutamic acid. Glycine is an aliphatic
amino acid with an apolar side chain, but glutamic acid is
an acidic amino acid which can be uncharged or negatively
charged depending on its local environment. Indeed,
glutamic acid is often found in the active site of proteins
or enzymes where its imidiazole ring can readily switch
between these states to catalyze the making and breaking of
bonds; so, this mutation can change the conformation of
normal protein. IHC revealed a lack of PMS2 protein
expression, and the tumor showed high MSI (four out of
five instable markers).
Our finding suggests that germline MMR mutations are
found in patients with MSS tumors. In all the patients, an
abnormal expression of the MMR proteins was related to
the above mutations.
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